title: Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns.
abstract: OBJECTIVE
  To investigate the preventive effect of ulinastatin on shock in the heart after burn.
  
  
  METHODS
  In an open prospective clinical study 34 adults with burns >50% total body surface area were randomly divided into control (B) and ulinastatin-treated (U) groups. All underwent routine treatment, and group U received 100,000U ulinastatin intravenously three times a day for 1 week. In an animal experiment, 72 healthy rats underwent equivalent burn, similar division into groups B and U, and resuscitation according to Parkland's formula. Rats in group U received ulinastatin (40,000U/kg) immediately after burn. Myocardial pathomorphology, plasma cTnI, CK-MB and PMNE, myocardial MDA, TNF-alpha, IL-10 and caspase-3 activity and cardiocyte apoptosis were determined.
  
  
  RESULTS
  Plasma cTnI, CK-MB, and PMNE were higher in clinical group B than group U. In the animal experiment, plasma cTnI, CK-MB, myocardial MDA, TNF-alpha, IL-10 and caspase-3 activity, and apoptotic index and myocardial pathomorphological changes were significantly less in group U than in group B, save IL-10.
  
  
  CONCLUSIONS
  The clinical and experimental data showed that ulinastatin relieved myocardial damage from severe burn. The mechanism might involve modulation of the anti- and pro-inflammatory balance and lipid peroxidation, and decreased myocardiocyte apoptosis.
authors.affiliation: Institute of Burn Research, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. yshuang@public.cta.cq.cn
authors.forename: Yuesheng
authors.initials: Y
authors.lastname: Huang
authors.forename: Kang
authors.initials: K
authors.lastname: Xie
authors.forename: Jiaping
authors.initials: J
authors.lastname: Zhang
authors.forename: Yongming
authors.initials: Y
authors.lastname: Dang
authors.forename: Zhang
authors.initials: Z
authors.lastname: Qiong
mesh_terms: D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002056:Burns / Q000097:blood / Q000150:complications* / Q000473:pathology; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D011446:Prospective Studies; D051381:Rats; D017207:Rats, Sprague-Dawley; D012770:Shock, Cardiogenic / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D019210:Troponin I / Q000097:blood; D055815:Young Adult
chemical_list: D002316:Cardiotonic Agents; D006023:Glycoproteins; D018836:Inflammation Mediators; D019210:Troponin I; C028665:urinastatin